Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.95B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 2.37M
Average 1.84M
DNLI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Denali Therapeutics Inc.NASDAQ: DNLI
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$124.9M, compared with -$121.04M a year earlier. Trailing-twelve-month EBITDA was -$498.21M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 15 analysts of -$296.23M (+40.5%) for the fiscal year ending Dec 2026, a step up from the -1.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$124.9M+0.6% QoQ
- Last fiscal yearDec 2025
- -$497.63M-1.0% YoY
- LTMJun 2026
- -$498.21M-6.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -3.2% | +60.6% | +63.8 pp |
| 1 year | -1.0% | +40.5% | +41.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (497.63M) USD
- Year-over-year change
- -1.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (497.63M) | -1.0% |
| FY2024 | 2024-12-31 | (492.89M) | -283.7% |
| FY2023 | 2023-12-31 | (128.47M) | +59.3% |
| FY2022 | 2022-12-31 | (315.59M) | -11.7% |
| FY2021 | 2021-12-31 | (282.56M) | — |
EBITDA vs competitors
How DNLI compares with its peers on the latest reported figures
- DNLI's LTM Jun 2026 EBITDA of -$498.21M is the 10th highest of the 11 companies compared; the peer median is -$139.56M.
- Its year-over-year change of -6.5% is the 6th highest of 11, against a peer median of -4.5%.
- EBITDA amounts to 13823.7% of revenue for DNLI, versus a peer median of 320.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $949.9M | +39.8% | +41.2% | 25.7% | |
| LTM Mar 2026 | -$19.31M | +41.5% | — | — | |
| LTM Jun 2026 | -$42.73M | -201.1% | — | — | |
| LTM Mar 2026 | -$116.42M | -1.3% | — | 632.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$118.15M | -28.2% | — | 590.7% |
| LTM Sep 2026 | -$160.97M | -7.8% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
| LTM Sep 2026 | -$359.29M | -31.7% | — | — | |
| LTM Sep 2026 | -$473.54M | -208.3% | — | 49.3% | |
| LTM Jun 2026 | -$498.21M | -6.5% | — | 13823.7% | |
| LTM Jun 2026 | -$574.94M | +24.1% | — | — | |
| Peer median (excluding DNLI) | -$139.56M | -4.5% | +41.2% | 320.0% | |
Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.66M | 108.46M | 330.53M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.18M |
| Gross Profit | 48.66M | 108.46M | 330.53M | 0 | (11.18M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 265.35M | 358.73M | 423.88M | 396.44M | 418.78M |
| Selling, General & Admin | 79.06M | 90.48M | 103.35M | 105.44M | 97.1M |
| Operating Expenses | 344.41M | 449.21M | 527.23M | 487.34M | 544.16M |
| Depreciation & Amortization | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| EBITDA | (282.56M) | (315.59M) | (128.47M) | (492.89M) | (497.63M) |
| EBITDA Margin | -580.7% | -291.0% | -38.9% | — | — |
| Operating Income | (295.75M) | (340.74M) | (196.7M) | (487.34M) | (555.34M) |
| Operating Margin | -607.8% | -314.2% | -59.5% | — | — |
| Interest Income | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Income Before Tax | (291.16M) | (325.97M) | (145.19M) | (422.71M) | (512.44M) |
| Pre-Tax Margin | -598.3% | -300.5% | -43.9% | — | — |
| Income Tax Expense | (575K) | 21K | 30K | 68K | 102K |
| Net Income | (290.58M) | (325.99M) | (145.22M) | (422.77M) | (512.54M) |
| Net Margin | -597.2% | -300.6% | -43.9% | — | — |
| EPS (Basic) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| EPS (Diluted) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| Weighted Avg Shares | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
| Weighted Avg Shares (Diluted) | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.